Zimmer Partners’s KalVista Pharmaceuticals KALV Stock Holding History

Zimmer Partners’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-95,704	Closed	-$811K	–	195
2024 Q4	$811K	Hold	95,704	–	–	0.01%	137
2024 Q3	$1.11M	Buy	95,704 +33,000	+53%	+$415K	0.02%	139
2024 Q2	$739K	Sell	62,704 -7,296	-10%	-$85.1K	0.01%	145
2024 Q1	$830K	Buy	+70,000	New	+$933K	0.02%	123

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Zimmer Partners's KALV Position: Q1 2025 in Review

Zimmer Partners sold out of KalVista Pharmaceuticals (KALV) in Q1 2025, closing a stake of 95,704 shares — an estimated $811K sold.

Zimmer Partners first reported a position in KALV in Q1 2024 and held it in 4 quarters. The position peaked at $1.11M in Q3 2024. 128 funds tracked by Wall St. Rank hold KALV as of Q1 2025.

Zimmer Partners reported no remaining KalVista Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Zimmer Partners sold 95,704 KalVista Pharmaceuticals shares in Q1 2025, an estimated $811K.
Zimmer Partners first reported a position in KalVista Pharmaceuticals in Q1 2024 and held it in 4 quarters.
Zimmer Partners's KalVista Pharmaceuticals position peaked at $1.11M in Q3 2024.
128 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2025.

Based on Zimmer Partners's 13F filing for Q1 2025, filed 15 May 2025.